Glaukos Stock Forecast, Price & News

Glaukos' stock was trading at $38.64 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GKOS stock has increased by 81.8% and is now trading at $70.23.
View which stocks have been most impacted by COVID-19.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 2 sell ratings, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Glaukos or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Glaukos a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Glaukos wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Glaukos is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Glaukos.

Glaukos Co. (NYSE:GKOS) posted its earnings results on Thursday, November, 5th. The medical instruments supplier reported ($0.09) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.46) by $0.37. The medical instruments supplier earned $64.83 million during the quarter, compared to analyst estimates of $53.74 million. Glaukos had a negative return on equity of 7.99% and a negative net margin of 33.61%. The business's revenue for the quarter was up 10.8% on a year-over-year basis. During the same period in the previous year, the company earned ($0.10) earnings per share.
View Glaukos' earnings history.

8 analysts have issued 12 month price targets for Glaukos' shares. Their forecasts range from $36.00 to $70.00. On average, they anticipate Glaukos' stock price to reach $52.75 in the next twelve months. This suggests that the stock has a possible downside of 24.9%.
View analysts' price targets for Glaukos.

Glaukos saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 4,990,000 shares, a decrease of 12.8% from the October 31st total of 5,720,000 shares. Based on an average trading volume of 581,300 shares, the short-interest ratio is currently 8.6 days.
View Glaukos' Short Interest.

Some companies that are related to Glaukos include Abiomed (ABMD), Penumbra (PEN), Hill-Rom (HRC), Globus Medical (GMED), Haemonetics (HAE), Tandem Diabetes Care (TNDM), Nevro (NVRO), Inspire Medical Systems (INSP), iRhythm Technologies (IRTC), Integra LifeSciences (IART), ICU Medical (ICUI), Merit Medical Systems (MMSI), ShockWave Medical (SWAV), Inari Medical (NARI) and Cantel Medical (CMD).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology Group (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and The Boeing (BA).

(GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Glaukos' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.80%), State Street Corp (3.20%), New York State Common Retirement Fund (2.32%), Natixis (1.47%), First Light Asset Management LLC (1.45%) and Wasatch Advisors Inc. (1.16%). Company insiders that own Glaukos stock include Chris M Calcaterra, David First, Gilbert H Kliman, Joseph E Gilliam, Thomas William Burns and William J Phd Link.
View institutional ownership trends for Glaukos.

GKOS stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, BNP Paribas Arbitrage SA, State of Tennessee Treasury Department, Blair William & Co. IL, State of New Jersey Common Pension Fund D, UBS Asset Management Americas Inc., Envestnet Asset Management Inc., and Truist Financial Corp. Company insiders that have sold Glaukos company stock in the last year include Thomas William Burns, and William J Phd Link.
View insider buying and selling activity for Glaukos.

GKOS stock was purchased by a variety of institutional investors in the last quarter, including Natixis, Point72 Asset Management L.P., JPMorgan Chase & Co., New York State Common Retirement Fund, BlackRock Inc., Morgan Stanley, Great West Life Assurance Co. Can, and SG Americas Securities LLC. Company insiders that have bought Glaukos stock in the last two years include David First, and Gilbert H Kliman.
View insider buying and selling activity for Glaukos.

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GKOS stock can currently be purchased for approximately $70.23.

Glaukos has a market capitalization of $3.16 billion and generates $236.98 million in revenue each year. The medical instruments supplier earns $15.42 million in net income (profit) each year or ($0.10) on an earnings per share basis. Glaukos employs 600 workers across the globe.

The official website for Glaukos is www.glaukos.com.

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected]